Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | ACE | P12821 | 7/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4611286 | 1.00 | FOLH1 (0.54) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL2703294 | 1.00 | FOLH1 (0.54) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL10494110 | 0.98 | FOLH1 (0.52) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL10494109 | 0.98 | FOLH1 (0.52) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| Trifluoroacetic Acid SCHEMBL29695528 | 0.92 | ACE (0.53) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL10537166 | 0.91 | FOLH1 (0.47) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL9052244 | 0.86 | FOLH1 (0.43) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL697901 | 0.86 | EPHX1 (0.61) | FOLH1NAALAD2MMEMEN1KMT2A | |
| SCHEMBL697900 | 0.86 | EPHX1 (0.61) | FOLH1NAALAD2MMEMEN1KMT2A | |
| SCHEMBL8211678 | 0.86 | EPHX1 (0.61) | FOLH1NAALAD2MMEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118883955-A | Alzheimer's disease biomarker and application thereof in early diagnosis | 南方医科大学珠江医院 | 2024-11-01 | — | — | CN | claimed |
| US-4725582-A | IMMUNE RESPONSE ENHANCERS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1988-02-16 | — | — | US | claimed |
| CN-119331778-A | Lactic acid bacteria composition for adjuvant treatment of diabetes and composite lactic acid bacteria probiotic and application thereof | 均瑶润盈生物科技(上海)有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-118883955-A | Alzheimer's disease biomarker and application thereof in early diagnosis | 南方医科大学珠江医院 | 2024-11-01 | — | — | CN | disclosed |
| EP-4267193-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | Ludwig-Maximilians-Universität München (DE) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022136555-A9 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022136555-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-30 | — | — | WO | disclosed |
| US-20220193251-A1 | CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-23 | — | — | US | disclosed |
| EP-2675487-B1 | NON-INVASIVE IN VIVO METHODS OF MONITORING BIODISTRIBUTION WITH RADIOLABELED COMPOUNDS | BOVIN NICOLAI VLADIMIROVICH (RU) | 2018-10-17 | — | — | EP | disclosed |
| US-10071990-B2 | Site-specific orthogonal labeling of the carboxy terminus of α-tubulin in live cells | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2018-09-11 | — | — | US | disclosed |
| US-10040823-B2 | In vivo methods of monitoring biodistribution | KODE BIOTECH LIMITED (NZ) | 2018-08-07 | — | — | US | disclosed |
| EP-2675487-A1 | IN VIVO METHODS OF MONITORING BIODISTRIBUTION | Bovin, Nicolai Vladimirovich (RU) | 2013-12-25 | — | — | EP | disclosed |
| WO-2013096823-A1 | CATIONIC PEPTIDES AND USE OF SUCH PEPTIDES FOR INHIBITING EXOTOXIN PRODUCTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-06-27 | — | — | WO | disclosed |
| WO-2012121610-A1 | IN VIVO METHODS OF MONITORING BIODISTRIBUTION | BOVIN NIKOLAI VLADIMIROVICH (RU) | 2012-09-13 | — | — | WO | disclosed |
| EP-2454229-A1 | AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | Kong, Xianqi (CA) | 2012-05-23 | — | — | EP | disclosed |
| WO-2010127439-A1 | AMMO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-11-11 | — | — | WO | disclosed |
| EP-1841460-A2 | THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-10-10 | — | — | EP | disclosed |
| WO-2007049098-A2 | THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-05-03 | — | — | WO | disclosed |
| EP-1644325-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004113275-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040823-B2 | In vivo methods of monitoring biodistribution | FABP1, FUCA1, LIPA | FOLH1 22/4885NAALAD2 373/4885SLC7A5 18/4885 |
| US-10071990-B2 | Site-specific orthogonal labeling of the carboxy terminus of α-tubulin in live cells | TUBB, TUBA1C, TUBB1 | FOLH1 220/4885NAALAD2 93/4885SLC7A5 2719/4885 |
| US-20220193251-A1 | CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | TUBB6, GALNT10, TUBB | FOLH1 120/4885NAALAD2 219/4885SLC7A5 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.